Case Report: A castration-resistant terminal prostate cancer patient’s survival prolonged after practicing Falun Gong

Background: Most metastatic prostate cancer patients receive combined androgen blockade (CAB) as the mainstay of treatment. Unfortunately, patients ultimately progress to castration resistance. Clinical finding and diagnosis: We describe a man in his eighties who developed stage IV, M1b prostate cancer, multiple (≥5) bone metastases, and required the aid of a walker to ambulate. Without treatment, his treating physician predicted he would survive 6 months. Interventions and outcomes: The patient initially responded well to treatment with CAB, but during the 68-80th week of treatment he developed castration resistance. Bicalutamide was then discontinued. He chose to begin practicing Falun Gong (FLG) at week 89 as an alternative form of care while continuing two doses of leuprolide acetate. His PSA decreased by 86% within five weeks, he walked independently at 17 weeks and bone metastases disappeared in 41-43 weeks after beginning to practice Falun Gong. He also reported better psychosocial functioning. His treating physician assessed that his prostate malignancy was “clinically, under control” and “his overall functional status is excellent.” The patient survived a total of 263 weeks (61.4 months) post-diagnosis, including 183 weeks (42.3 months) after developing castration resistance. Conclusion: This castration-resistant terminal prostate cancer patient gained significant clinical benefits after practicing Falun Gong.